This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Indian Guidelines on Pneumococcal Vaccination With PCV13 and PPSV231
Adults Aged 19 to 64 Years
In immunocompetent patients with chronic conditions,* a single dose of PCV13 followed by PPSV23 ≥8 weeks later is recommended.
In adults with a history of IPD, those with cochlear implants, CSF leak or impaired splenic function, a single dose of PCV13 followed by PPSV23 ≥8 weeks later is recommended
In all immunocompromised individuals,† administering a single dose of PCV13 followed by PPSV23 ≥8 weeks later is recommended
Adults Aged 65 years or Older
Vaccination with PCV13 first, followed by PPSV23, is usually recommended for individuals who have immunocompromising conditions, functional or anatomic asplenia, cochlear implant, CSF leak or history of IPD.
For adults with chronic conditions,* the decision to administer a dose of PCV13 preceding PPSV23 should be taken jointly by the physician and the patient, on a case-to-case basis.
The Indian guidelines are different from the ACIP guidelines, in terms of recommendation regarding vaccination with PCV13 vaccine
The ACIP guidelines are based on the fact that in the US, PCV13 is being administered to all children since the year 2010, and therefore, there is herd immunity, which prevents adults from being affected by the 13 serotypes covered in PCV13
In India, pneumococcal vaccination in the paediatric immunisation schedule has only been incorporated recently. Thus, the concept of herd immunity is not applicable
Hence, in the current guidelines, for individuals aged 19 to 64 years and with health conditions,*,† ICS/NCCP recommends vaccination with PCV13 followed by PPSV23.
*Such as chronic heart disease, chronic liver disease, poorly controlled diabetes mellitus, chronic lung disease and in current smokers and those with alcohol abuse.
†such as those with HIV infection, iatrogenic immunosuppression, chronic kidney disease, haematologic malignancy, other solid tumour malignancies with or without metastasis, HSCT and solid-organ transplantation.
CSF, cerebrospinal fluid; HSCT, haematopoietic stem cell transplant; ICS/NCCP, Indian Chest Society/National College of Chest Physicians; IPD, invasive pneumococcal disease; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.